Sarah Gheuens has sold AGIO and made no open-market buys since Jun 2023

Sarah Gheuens, M.D., Ph.D. is the Chief Medical Officer (CMO) and Head of Research & Development at Agios Pharmaceuticals, Inc. (AGIO).( She joined Agios in December 2019 as head of clinical development for genetically defined disease programs and interim head of regulatory affairs, became CMO in September 2021, and assumed R&D leadership in August 2022.( Under her tenure, she led the pivotal Phase 3 programs for pyruvate kinase deficiency (resulting in regulatory submissions to FDA and EMA), thalassemia, and sickle cell disease, with key 2024 milestones including positive Phase 3 readouts in thalassemia (ENERGIZE/ENERGIZE-T) and sNDA acceptance by FDA (PDUFA September 7, 2025).( Recently, as a corporate insider, she sold 2,932 shares of AGIO stock on December 30, 2025.(

Prior to Agios, Dr. Gheuens held roles of increasing responsibility at Biogen (2012–2019) in safety, medical affairs, and clinical development, contributing to the approval of SPINRAZA® for spinal muscular atrophy, and worked as a physician-scientist at Beth Israel Deaconess Medical Center (2008–2012) treating HIV patients with neurological complications and researching progressive multifocal leukoencephalopathy.( She serves on the Board of Directors and Science & Technology Committee at Viridian Therapeutics, Inc.( Dr. Gheuens earned her M.D. from the Free University of Brussels (VUB), completed neurology residency and HIV/neurology fellowship there and at BIDMC, holds a Ph.D. in Medical Sciences from the University of Antwerp, and a Master’s in Medical Sciences from Harvard Medical School.(

Written by Perplexity from public sources.